Richard Close, an analyst from Canaccord Genuity, maintained the Buy rating on Privia Health Group. The associated price target remains the same with $35.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Richard Close has given his Buy rating due to a combination of factors, including Privia’s solid momentum and attractive long-term positioning in value-based care. He expects first-quarter results may show some mixed signals given industry-wide issues like softer respiratory volumes and weather, yet he remains confident that Privia can sustain operating efficiencies and protect profitability.
Close also anticipates the company will reaffirm its annual outlook, noting that management likely incorporated early-quarter trends when setting guidance. He is encouraged by management’s upbeat tone on larger-scale business development opportunities, the robust pipeline, and ongoing margin expansion, including the potential for AI-driven gains, which together support maintaining a $35 price target and a Buy recommendation.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRVA in relation to earlier this year.